Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $29.50 Average Target Price from Brokerages
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
Arcturus Therapeutics to Attend Upcoming Investor Conference
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving Average – Should You Sell?
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
Arcturus Therapeutics to Attend Upcoming Investor Conference
Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Target Price at $36.00
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm
Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT
Cathie Wood Goes Shopping: 3 Stocks She Just Bought
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture
Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results
Arcturus Crashes 55% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?
4 Stocks With Recent Price Strength to Maximize Your Gains
Arcturus Therapeutics (ARCT) is on the Move, Here's Why the Trend Could be Sustainable
Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?
Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Citi adds 'upside 90-day catalyst watch' on Arcturus Therapeutics
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet